Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD

European Academy of Dermatology and Venereology (EADV) Congress

 functions as both a yearly meeting of clinicians in dermatology and a place in which new late-breaking data and insightful sessions exploring dermatologic disease states help to redefine treatment approaches in the 

The 2025 EADV Congress is set to take place in Paris, France, from September 17–20. The 

 team spoke about what to look forward to at EADV with Raj Chovatiya, MD, PhD, clinical associate professor at Rosalind Franklin University Chicago Medical School and director of the Center for Medical Dermatology and Immunology Research, and Linda Stein Gold, MD, the director of dermatology clinical research and division head of dermatology at the Henry Ford Health System.

What to Expect at EADV Congress 2025, With Raj Chovatiya, MD, PhD, and Linda Stein Gold, MD

"EADV is one of our biggest conferences of the year, and it's really a chance where a lot of the dermatology world comes together outside of the US, including some folks in the US too, to talk about what's happening in dermatology," Chovatiya said. "This year, beyond the usual of meeting my colleagues and catching up with people I don't get to see all that often, I'm really excited for a lot of the newer data presentations that are happening in the atopic dermatitis world."

Chovatiya highlighted that a number of late-breakers and oral presentations on some of the newer mechanisms of action that are being discussed in the dermatology world are to be included in the meeting. A list of late-breakers set to be presented at EADV can be found 

"I'm really excited to hear about some updates and some of the newer mechanisms, like the OX40 and OX40 ligand, as well as some even earlier phase mechanisms too, where we don't necessarily know what the future holds for their ability to become a commercialized drug," Chovatiya explained. "There's also long term updates, and some of the drugs that we're quite familiar with too, ones that we actually have available to us, both in a topical, oral and biologic realm as well."

Stein Gold also expressed her own excitement in anticipation of the EADV Congress 2025, echoing Chovatiya's sentiments regarding the variety of important data to be presented on treatments for conditions such as atopic dermatitis and psoriasis.

"This is always a very important meeting," Stein Gold said. "I'm interested in seeing what's going on in atopic dermatitis. We have some new drugs that are pretty much finishing up [their] phase 3 clinical trials. We have some long term efficacy and safety information on the OX40 drugs. So I'm really excited to see what's going on with that."

Stein Gold noted that there are data related to psoriasis treatments, including an oral, interleukin (IL)-23 medication for this prominent skin disease.

"We know we have the oral, IL-23 drug and this is very exciting," Stein Gold explained. "It could be a game changer for the oral therapy arena, for our psoriasis patients and a lot more. So I'm going to be there and I'll be taking notes. I'm sure I'm going to be taking home some important kernels of truth that will help make me a better clinician."

For updates on EADV coverage next week, view the 

The quotes contained in this interview were edited for clarity. 

Raj Chovatiya has reported serving as an adviser, a consultant, a speaker or an investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CLn Skin Care, Dermavant, Eli Lilly, EMD Serono, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L'Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio and UCB.

Stein Gold has served as an investigator, advisor, and/or speaker for AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte Corporation, Ortho Dermatologics, Pfizer, Regeneron, and Sanofi and she has reported personal fees from AbbVie, Amgen, Arctis, Bristol MyerSquibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.

HCPLive Editorial Staff. EADV Congress 2025: Late-Breaking Trials Preview. HCPLive. September 9, 2025. Accessed September 12, 2025. 

https://www.hcplive.com/view/eadv-congress-2025-late-breaking-trials-preview

Videos

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

Many clinicians in the field of dermatology have noted that recent years have seen huge growth in the number of options available for 

, including a variety of topical options.

However, many clinicians will still resort to topical steroids over other non-steroidal alternatives. In this interview at the 

Dermatology Education Foundation (DERM) 2025 NP/PA CME Conference

, Linda Stein Gold, MD, of the Henry Ford Health System, spoke with 

 about her talk on the subject of topicals for psoriasis.

Highlighting Recent Topical Options for Psoriasis, with Linda Stein Gold, MD

“We've really learned a lot about topical therapy, and when we think about psoriasis, topical corticosteroids have been the go-to,” Stein Gold explained. “We use really potent topical steroids like clobetasol for flares. We use maybe triamcinolone cream for maintenance therapy. We use desonide or hydrocortisone for sensitive areas. And when you think about all the prescriptions that we're writing, and maybe we're using some of the traditional non-steroidals, the patients end up with all these prescriptions. They are almost incapacitated by fear, because there are so many things to do. They forget what they're supposed to do. So in the end, they end up using their clobetosol indefinitely.”

Stein Gold highlighted that potent topical steroids are not the solution to the treatment of psoriasis. She described them as a short-term answer to a long-term solution.

“We have some non-steroidal options, and we're really excited about the new ones that we have,” Stein Gold said. “They've been around for a little while now. Tapinarof, which is an oral hydrocarbon receptor agonist that works inside the cell, has been shown to work even as monotherapy. Not only to get the disease under control, but to keep it under control. The good news with these non-steroidals is that you can use them on the face, you can use them on the hands. You can use them on thick areas.”

Stein Gold noted that if such patients are treated until clear, they can have a durable remission that can last 4 months or longer in such patients.

“We also have topical roflumilast, which is a phosphodiesterase type 4 inhibitor,” Stein Gold explained. “And we've seen PDE4 inhibitors in the past. But this one's different. It's very potent. It's a topical that can also be used as monotherapy, again, to get patients under control and keep them under control. We [also] have a foam formulation that was recently FDA-approved.”

For any additional information on Stein Gold’s talk, view her full interview segment posted above. To find out more about clinical pearls highlighted at the meeting, view our 

The quotes used in this interview summary were edited for clarity.

Stein Gold has previously reported personal fees from AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.

Stein Gold L. Psoriasis Topicals: Totally Tubular. Presented at DERM 2025 NP PA CME Conference; July 23-26, 2025; Las Vegas, Nevada.

In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.

Linda Stein Gold, MD, Reacts to Delgocitinib Approval for Chronic Hand Eczema

On July 23, 2025, Leo Pharma announced that the 

 approved delgocitinib (Anzupgo) cream for the treatment of moderate-to-severe 

 This marks the first FDA-approved treatment for chronic hand eczema.

The FDA based its decision on data from DELTA 1 and DELTA 2, phase 3 randomized, double-blind, vehicle-controlled trials evaluating delgocitinib in patients aged ≥ 18 years. The primary endpoint was the Investigator’s Global Assessment for CHE Treatment Success (IGA-CHE TS) at week 16 with ≥ 2-point improvement from baseline.

In DELTA 1, 20% of patients treated with delgocitinib achieved IGA-CHE TS compared with 10% of those receiving vehicle (

 = .006). Similarly, in DELTA 2, 29% of patients who received delgocitinib achieved this endpoint compared to 7% with vehicle (

Following this historic approval in the dermatology space, 

 spoke with Linda Stein Gold, MD, a dermatologist at Henry Ford Health, on what this approval means for the unmet need in chronic hand eczema.

“For a lot of our patients, it's more moderate or severe, and that means that they have hands that are unable to really work in our everyday needs,” Gold said. “Imagine if your hands are painful and itchy and fissured, you're in a professional setting, and somebody puts out their hand to shake your hand, and you feel humiliated because your hands are maybe red and cracked and bleeding. So not only is it physically uncomfortable, but it's emotionally devastating for our patients, because it really does impact every aspect of their lives.”

She said that household chores—washing dishes or opening jars—can be difficult for these patients. Chronic hand eczema is also common, affecting 10% of adults worldwide. Until now, no FDA-approved treatments existed for moderate to severe chronic hand eczema, which is why many patients received topical corticosteroids.

However, as Gold pointed out, topical corticosteroids are intended for short-term use. Using topical corticosteroids for chronic hand eczema requires repeated application to the skin, but this can lead to local adverse events, such as skin thinning.

Gold believes the approval of delgocitinib is a huge step forward in helping patients, and this space deserves further development.

“We might see new drugs on the horizon in the future, but I think what doctors are looking for ideally is something that's topical,” Gold said. “Ideally, we like to use something that gets right at the heart of the disease, something that doesn't have systemic complications. If we can manage this with topical therapy safely and effectively, that's really a win-win for our patients as well as our prescribers. We'll see what the future holds.”

Campbell, P. Delgocitinib (Anzupgo) Scores FDA Approval for Chronic Hand Eczema. HCPLive. July 23, 2025. 

https://www.hcplive.com/view/delgocitinib-anzupgo-fda-approved-for-chronic-hand-eczema

LEO Pharma. LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S. LEO Pharma. Published July 23, 2025. Accessed July 23, 2025. 

https://www.leo-pharma.com/media-center/news/2025-fda-approval

FDA approval of topical delgocitinib marks a long-awaited treatment milestone for adults with chronic hand eczema.

Key Takeaways on the Role of Oral JAK Inhibitors in Atopic Dermatitis Management

Video content above is prompted by the following:

What are some key takeaways or advice for other dermatologists treating patients with atopic dermatitis with JAK inhibitors?

Experts discuss key takeaways for dermatologists managing atopic dermatitis with JAK inhibitors, emphasizing the importance of individualized treatment plans, monitoring for safety and efficacy, and balancing the benefits of JAK inhibitors with potential risks, especially in long-term use.

Linda Stein Gold, MD

Articles